Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc.

Overview
Date Founded

2003

Headquarters

300 THIRD STREET, 3RD FLOOR, CAMBRIDGE, MA, 02142

Type of Company

Public

Employees (Worldwide)

1,453

Industries

Pharmaceuticals
Hospitals & Patient Services
Medical Support Services
Biotechnology

Company Description

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. The firm's products include ONPATTRO, GIVLAARI, and OXLUMO. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Contact Data
Trying to get in touch with decision makers at Alnylam Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

President & Chief Operating Officer

Chief Financial & Accounting Officer

Chief Commercial Officer

Chief Ethics & Compliance Officer

Chief Information Officer & Senior Vice President

Chief Technical Operations & Quality Officer

Chief Medical Officer

Executive Vice President, Chief Legal Officer & Secretary

Chief Human Resources Officer & Senior Vice President

Board of Directors

Executive Officer, Director at Adolor Corp.

Co-Founder at Alnylam Pharmaceuticals, Inc.

Co-Founder at Lyndra Therapeutics, Inc.

President at International Council of Ophthalmology Foundation

Former Venture Partner at Third Rock Ventures LLC

Former Chief Financial Officer & Senior Vice President at Takeda Oncology Co.

Former Foreign Secretary at Institute of Medicine

Physician in Chief Emeritus of Medicine at The Massachusetts General Hospital

Vice President & Member at European Federation Of Pharmaceutical Industries And Associations

Former Executive Vice President & Chief Operating Officer at Health Care Service Corp.

Paths to Alnylam Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
You
Alnylam Pharmaceuticals, Inc.
Owners & Shareholders
Details Hidden

Baillie Gifford is an active, team-oriented, research-based manager which is completely focused on delivering long-term returns. The firm’s investment philosophy focuses on growth while their universe is global. They employ bottom-up conviction to portfolio construction. Their diversified strategies maximize investment opportunities, aiming to achieve steady returns. For equities, Baillie Gifford’s analysts conduct qualitative, fundamental analysis to identify the most competitive, innovative and efficient growth companies. For multi-asset strategy, the firm invests in various asset classes such as listed equities, property, high yield credit, commodities, emerging market government bonds and insurance linked securities. For fixed-income, Baillie Gifford invests in government bonds and currencies, emerging market bonds, investment grade and high yield.

Details Hidden

Manulife IM-US utilizes a broad range of equity, fixed income, currency and asset allocation approaches. They manage differentiated investment processes and place an emphasis on proprietary fundamental research, but also employ quantitative analysis. The firm’s equity investment strategies utilize a wide array of asset approaches, including investment in growth, core, value, global, region-specific, international, emerging market and industry-specific securities. Some strategies also include investments focused on sectors, dividend income and/or small, mid and/or large-cap companies. Some of their equity strategies include a fixed income component for a balanced portfolio. Research combines quantitative and qualitative bottom-up fundamental analysis. Manulife IM-US’ fixed income management teams engage in intensive fundamental research and analysis, both top-down and bottom-up, to assess potential investment opportunities.

Details Hidden

RTW Investments aims to generate attractive risk-adjusted returns through investments in securities, both equity and debt, long and short, of companies with a focus on the healthcare sector. The Funds will primarily invest in the equity and debt of public and private issuers globally, with a focus on the US and Europe. Derivatives are employed to improve payoff structures, as well as to construct hedges. The firm’s research process will be focused on a scientific approach to assessing and accurately defining the fundamental value of outcomes surrounding transformational events in the lifecycle of healthcare companies.

Recent Transactions
Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Details Hidden

Alnylam Pharmaceuticals, Inc. issued USD Common Stock

Insider Transactions
Details Hidden
Details Hidden
Details Hidden
Transaction Advisors
Auditor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Escrow Agent

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Chair, Life Sciences Practice

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Managing Director

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Legal Advisor

Advised onAlnylam Pharmaceuticals, Inc. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Goodwin Procter LLP

Legal Advisor

Chair, Transactional Department at Wilmer Cutler Pickering Hale and Dorr LLP

Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Clients

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Vir Biotechnology, Inc. operates as a clinical-stage immunology company that focuses on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. The firm's technology platforms include antibody, T cell, innate immunity and siRNA, which are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. The company was founded by Robert Taylor Nelsen, Klaus Frueh, Jay Parrish, Lawrence Corey, and Louis Picker in April 7, 2016 and is headquartered in San Francisco, CA.

Key Stats and Financials As of 2020
Market Capitalization
$15.8B
Total Enterprise Value
$14.7B
Earnings Per Share
$-7.46
Revenue
$493M
Enterprise Value / Sales
29.75x
TEVNet Income
-17.08x
Debt TEV
0.11x
Net Profit
$-858M
Total Equity
$1.02B
Total Debt
$1.59B
EBITDAMargin
-161.04%
EBITDA
$-794M
Three Year Compounded Annual Growth Rate Of Revenue
76.32%
Non-Profit Donations & Grants
$2,500 - $4,999
2018
$5,000 - $10K
2017
Investors
Details Hidden

Investor at Alnylam Pharmaceuticals, Inc.

Details Hidden

Polaris Partners invests primarily in companies in the consumer technology, digital media/entertainment, e-Commerce, network hardware, software and semiconductors sectors. They invest in seed, early-stage and high growth, middle-market companies.The firm's early-stage investments focus on information technology and life sciences companies. Within the information technology sector, Polaris looks for companies that are developing Internet and broadband infrastructure, enterprise software products, e-Commerce products/services, digital media/entertainment, consumer software, network hardware and network software.In the life sciences sector, the firm looks for companies that are developing medical devices, pharmaceuticals, genomics, proteomics, drug delivery, medical services and consumer products and services.Polaris' private equity efforts focus on high-growth, middle-market companies in industries including technology, healthcare, digital media, consumer products and services and business services.Polaris serves as the lead or co-lead investor in the vast majority of their portfolio companies. The firm participates in minority growth equity investments, recapitalizations with liquidity and LBOs.

Details Hidden

ARCH Venture Partners focuses on seed and early-stage investments in start-up technology companies, with a particular interest in the life sciences, the physical sciences and information technology. Their life sciences investments focus on biotechnology, pharmaceuticals, medical instrumentation and informatics. Their physical sciences investments focus on companies that are pioneering technology with a range of commercial applications in chemicals/materials, electronics/instrumentation and medical instrumentation industries. The firm's focus within the information technology sector includes electronics/hardware, information, infrastructure/software and commerce. ARCH Venture Partners invests primarily in companies located in the southwestern, Midwestern, eastern seaboard and northwestern sections of the US. The firm exits most of their investments through IPOs or private sales.

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust. It engages in the ownership, operation, development, and redevelopment of life science and technology properties. The firm also provides a space for lease to the life science and technology industries, which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

Massachusetts Institute of Technology Hospitals & Patient Services | Cambridge, Massachusetts

Massachusetts Institute of Technology (MIT) is a private research university located in Cambridge, Massachusetts, United States. MIT has five schools and one college, containing a total of 32 academic departments, with a strong emphasis on scientific, engineering, and technological education and research. Founded in 1861 in response to the increasing industrialization of the United States, the institute used a polytechnic university model and stressed laboratory instruction. MIT was elected to the Association of American Universities in 1934.

Ionis Pharmaceuticals, Inc. Medical Support Services | Carlsbad, California

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Competitors
Regeneron Pharmaceuticals, Inc. Pharmaceuticals - Tarrytown, New York

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Arbutus Biopharma Corp. Pharmaceuticals - Burnaby, Canada

Arbutus Biopharma Corp. engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded in 2007 and is headquartered in Warminster, PA.

Awards & Honors
2009
World Economic Forum - Technology Pioneers
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Alnylam Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Alnylam Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Alnylam Pharmaceuticals, Inc..